SEIKOU PHARMA SL
Company details
- Active NIF/CIF: B87914487
-
-
-
-
Address: AVDA DEL PUENTE CULTURAL,NUMERO 8, BLOQUE A, BAJO (SAN SEBASTIAN DE LOS REYES.
-
-
Featured products:

More information on SEIKOU PHARMA SL
-
21/10/2024 | BORME act no.: 448060 | Register: MADRIDCambio de denominación social
-
21/10/2024 | BORME act no.: 448060 | Register: MADRIDCambio de domicilio social
-
05/11/2020 | BORME act no.: 379362 | Register: MADRIDPérdida del caracter de unipersonalidad
-
08/10/2019 | BORME act no.: 417478 | Register: MADRIDAmpliacion del objeto social
-
08/10/2019 | BORME act no.: 417478 | Register: MADRIDCambio de domicilio social
-
25/10/2017 | BORME act no.: 420152 | Register: MADRIDConstitución
-
25/10/2017 | BORME act no.: 420152 | Register: MADRIDDeclaración de unipersonalidad
-
25/10/2017 | BORME act no.: 420152 | Register: MADRIDNombramientos
Other information
The CIF of SEIKOU PHARMA SL is B87914487 and its current business status is active. The company is engaged in activities related to the CNAE code 8230 - Organización de convenciones y ferias de muestras. Its SIC code - also indicates the nature of its business.
SEIKOU PHARMA SL employs a number of workers ranging from Between 1 and 9 employees, and records an annual turnover of less than 2 million euros. The company is registered in the Mercantile Registry of Madrid and has a total of 2 registry positions.
Its last announcement in Borme was published on 21/10/2024, while its last deposit of ordinary annual accounts corresponds to the year 2023.
You can find contact information for SEIKOU PHARMA SL, such as phone number, address, or website, in the Company Data section.
For more details about SEIKOU PHARMA SL, you can review one of our available financial reports, the Annual Accounts of the company, or check its default incidents in the RAI delinquency file.
The financial, business, and legal information provided for SEIKOU PHARMA SL comes from official sources and is updated daily.
Do you want to know more about SEIKOU PHARMA SL??
Find out more about this company by consulting these reports: